Should we consider aldosterone as the primary screening target for preventing cardiovascular events?

Gary S. Francis; W. H.Wilson Tang

doi:10.1016/j.jacc.2005.01.014

Should we consider aldosterone as the primary screening target for preventing cardiovascular events?

Gary S. Francis, W. H.Wilson Tang

Medicine - Cardiology Division

Research output: Contribution to journal › Editorial › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1249-1250
Number of pages	2
Journal	Journal of the American College of Cardiology
Volume	45
Issue number	8
DOIs	https://doi.org/10.1016/j.jacc.2005.01.014
State	Published - Apr 19 2005

Bibliographical note

Funding Information:
Dr. Francis is a consultant for Novartis Pharmaceuticals and has received a research grant from Pfizer Pharmaceuticals to study eplerenone.

Publisher link

10.1016/j.jacc.2005.01.014

Find It

Find It at U of M Libraries

Cite this

@article{71c92a94db1946a9b58417880c789f54,

title = "Should we consider aldosterone as the primary screening target for preventing cardiovascular events?",

author = "Francis, {Gary S.} and Tang, {W. H.Wilson}",

note = "Funding Information: Dr. Francis is a consultant for Novartis Pharmaceuticals and has received a research grant from Pfizer Pharmaceuticals to study eplerenone. ",

year = "2005",

month = apr,

day = "19",

doi = "10.1016/j.jacc.2005.01.014",

language = "English (US)",

volume = "45",

pages = "1249--1250",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",